Challenges of Treating Acute Coronary Syndrome

Published Online: Monday, March 25, 2013
Follow Pharmacy_Times:
In this video, from AJMCtv, Peter Berger, MD, FACC, FAHA, chairman of cardiology and co-director of the Geisinger Heart & Vascular Institute and director of the Cardiovascular Center for Clinical Research at Geisinger Clinic in Danville, Pennsylvania, discusses the challenge of individualizing antiplatelet treatment for acute coronary syndrome (ACS) patients.

Related Articles
Cardiovascular disease (CVD) continues to be the leading cause of death in both men and women in the United States, accounting for an estimated 1 in 4 deaths.
CONMED Corporation is voluntarily recalling some of its PadPro and R2 multi-function defibrillation electrodes due to a connector compatibility problem with Philips FR3 and FRx defibrillator units.
Digoxin is associated with a 71% increased risk of death and a 63% higher risk of hospitalization among adults diagnosed with atrial fibrillation who have no evidence of heart failure.
A Merck study found patients who received a cholesterol-lowering combination of ezetimibe/simvastatin experienced fewer major cardiovascular events than those taking simvastatin alone.
Latest Issues
$auto_registration$